| Literature DB >> 35335225 |
Abstract
The sesquiterpene γ-lactone estafiatin 1, the molecule of which has a structure of 3,4α-epoxy-1,5,7α,6β(H)-guai-10(14),11(13)-dien-6,12-olide, is characteristic of plants of the genera Achillea L. and Artemisia L. of the Asteraceae family. This article presents the results of chemical modification for three reaction centers of the estafiatin molecule 1: epoxy cycle, exomethylene group conjugated with γ-lactone carbonyl, and exomethylene group in position C10=C14; and at the same time 33 new derivatives were synthesized, the structures of which were established based on physicochemical constants, spectral data (IR-, PMR-, 13C-NMR), and X-ray diffraction analysis. The stereo- and regiospecificity, as well as the chemoselectivity of the reaction based on estafiatin molecule 1, are discussed. The reactivity of the substrate is significantly influenced by the stereochemistry of its molecule, the nature of the reagent, and the reaction medium. Based on the results of in silico screening, derivatives of estafiatin with high binding energies for both DNA-topoisomerase I and DNA-topoisomerase II were identified. The values of the inhibitory dose of IC50 for estafiatin 1 and its derivatives were determined on cell lines of eight types of tumors. in vivo experiments of the samples made it possible to establish that estafiatin 1 and its derivatives have pronounced antitumor activity against Pliss lymphosarcoma, Walker's carcinosarcoma, sarcoma 45, sarcoma-180, alveolar liver cancer PC-1, leukemia P-388 and L-1210, and sarcoma-45 resistant to 5-fluorouracil.Entities:
Keywords: antitumor activity; chemical modification; cytotoxicity; estafiatin; guaianolide; in vitro; in vivo; molecular docking; regio-, stereospecific and chemoselective synthesis; sesquiterpene lactones
Mesh:
Substances:
Year: 2022 PMID: 35335225 PMCID: PMC8949978 DOI: 10.3390/molecules27061862
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1Structure of estafiatin 1.
Scheme 1Conversions on the epoxy cycle of estafiatin 1.
Chemical shifts (in ppm) and spin–spin coupling constants (1H NMR, 500.16 MHz, CDCl3, δ, ppm, in brackets, in Hz) for estafiatin 1 and its derivatives 2–10.
| No. | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 |
|---|---|---|---|---|---|---|---|---|---|---|
| Me-4 | 1.53 s | - | - | - | 1.22 d (6) | 1.34 s | 1.51 s | 1.74 s | 1.18 s | 1.21 s |
| H-3 | 3.28 br.s | 4.68 | 5.62 br.t (6) | - | 4.26 | 3.94 br.d (3) | 5.33 | 3.75 t | 3.70 t | |
| H-4 | - | - | - | - | 2.50 m | - | - | - | - | - |
| H-6 | 4.01 q (10.5:9) | 3.90 | 3.99 | 3.87 | 3.95 | 4.17 | 4.23 q (10.5;9) | 4.39 | 3.87 | 3.90 |
| H-13a | 5.42 d (3.5) | 5.48 | 5.56 | 5.47 | 5.52 | 5.58 | 5.48 | 5.51 | 5.43 | 4.84 |
| H-13b | 6.12 d (3.5) | 6.21 | 5.85 | 6.18 | 6.22 | 6.26 | 6.20 | 6.22 | 6.15 | 6.0 d (2,5) |
| H-14a | 4.78 br.s | 4.78 br.s | 4.67 s | 4.76 br.s | 4.62 br.s | 5.01 br.s | 4.94 br.s | 5.08 br.s | 5.93 | 5.71 br.s |
| H-14b | 4.78 br.s | 4.90 br.s | 4.91 s | 4.90 br.s | 4.92 br.s | 5.08 br.s | 4.94 br.s | 5.08 br.s | 5.93 | 5.71 br.s |
| H-15a | - | 5.35 br.s | 6.23 | 5.36 br.s | - | - | - | - | - | - |
| H-15b | - | 5.45 br.s | 6.28 | 5.51 br.s | - | - | - | - | - | - |
| Other protons | - | - | - | –OAc 2.02 s | - | - | - | –OAc | (–NH–C(O)CH3)2 1.23 s, (6H) | Aromatic ring |
Figure 2Structures of amino derivatives of estafiatin 9, 10.
Scheme 2Preparation of epoxy derivatives of estafiatin 11–16.
Chemical shifts (in ppm) and spin–spin coupling constants (1H NMR, 500.16 MHz, CDCl3, δ, ppm, in brackets, in Hz) for estafiatin derivatives 11–14.
| No. | Me-4 | H-4 | H-6 | H-13a | H-13b | H-14a | H-14b |
|---|---|---|---|---|---|---|---|
|
| 1.24 d (6.5) | 2.35 m | 4.41 t (9.5) | 5.58 d (3.5) | 6.29 d (3.5) | 2.42 d (4) | 2.61 d (4) |
|
| 1.19 d (7) | 2.25 m | 4.36 t (10) | 5.52 d (3) | 6.24 d (3) | 2.51 d (4.5) | 2.73 d (4.5) |
|
| 1.50 d (6,5) | 4.78 q (12.5;6.5) | 4.17 q (10.5;9) | 5.76 d (3) | 6.31 d (3) | 2.76 d (4.5) | 2.82 d (4.5) |
|
| 1.32 d (6.5) | 4.72 q (12.5;6.5) | 4.36 t (9.5) | 5.39 d (3) | 6.20 d (3) | 2.56 d (4.5) | 2.78 d (4.5) |
Figure 3Structures of phosphonate derivatives of estafiatin 17–20.
1H NMR spectra data for derivatives 17–20 (500.16 MHz, CDCl3, δ, ppm, J/Hz).
| H Atom | 17 | 18 | 19 | 20 |
|---|---|---|---|---|
| 1 | 2 | 3 | 4 | 5 |
| 1 | 2.87 (ddd, J = 10.5, 9.0, 1.0) | 2.88 (ddd, J = 10.5, 8.0, 1.0) | 2.87 (ddd, J = 9.0, 10.5, 1.0) | 2.87 (ddd, J = 9.0, 10.5, 1.0) |
| 2a | 1.76 (ddd, J = 14.0, 10.5, 1.0) | 1.76 (ddd, J = 13.7, 10.5, 1.0) | 1.76 (ddd, J = 13.7, 10.5, 1.0) | 1.76 (ddd, J = 13.7, 10.5, 1.0) |
| 2b | 2.03–2.10 m | 2.04–2.09 m | 2.03–2.13 m | 2.03–2.13 m |
| 3 | 3.33 (d, J = 1.0) | 3.34 (d, J = 1.0) | 3.33 (d, J = 1.0) | 3.37 (d, J = 1.0) |
| 5 | 2.27–2.29 m | 2.3–2.37 m | 2.32–2.36 m | 2.31–2.35 m |
| 6 | 3.99 (dd, J = 10.5, 9.0) | 4.0 (t, J = 10.5, 9.5) | 3.99 (dd, J = 10.5, 9.5) | 3.99 (dd, J = 10.6, 9.6) |
| 7 | 2.21–2.26 m | 2.23–2.28 m | 2.16–2.25 m | 2.15–2.25 m |
| 8a | 2.21–2.26 m | 2.17–2.25 m | 2.22–2.27 m | 2.22–2.27 m |
| 8b | 2.03–2.13 m | 2.08–2.15 m | 2.03–2.13 m | 2.03–2.13 m |
| 9a | 1.36 m | 1.36 m | 1.35 m | 1.31–1.41 m |
| 9b | 2.21–2.26 m | 2.17–2.26 m | 2.16–2.25 m | 2.15–2.25 m |
| 11 | 2.53 (dddd, J = 12.0, 7.5, 5.0, JPH = 20.5) | 2.53 (dddd, = 12.0, 7.2, 4.5, JPH = 21.5) | 2.52 (dddd, J = 11.8, 7.4, 4.4, JPH = 22.1) | 2.52 (dddd, = 11.8, 7.4, 4.7, JPH = 22.0) |
| 13a | 2.34 (ddd, J = 16.2, 5.0, JPH = 19. 5) | 2.34 (ddd, J = 15.7, 4.5, JPH = 20.0) | 2.34 (ddd, J = 15.7, 4.5, JPH = 20.0) | 2.33 (ddd, J = 16.2, 4.7, JPH = 19.4) |
| 13b | 1.90 (ddd, J = 16.2, 7.5, JPH = 18.4) | 1.90 (ddd, J = 15.7, 7.2, JPH = 18. 0) | 1.97 (ddd, J = 15.7, 7.4, JPH = 18.3) | 1,92 (ddd, J = 16.2, 7.4, JPH = 18.0) |
| 14a | 4.85 (t, J = 1.0) | 4.86 s | 4.84 (t, J = 1.0) | 4.89 (t, J = 1.0) |
| 14b | 4.78 (d, J = 1.0) | 4.80 s | 4.79 (d, J = 1.0) | 4.84 (d, J = 1.0) |
| 15 | 1.54 (3H, s) | 1.55 (3H, s) | 1.54 (3H, s) | 1.59 (3H, s) |
| 1’ | 3.73 (3H, d, JPH = 5.0) | 4.09 (4H, m) | 3.96 (4H, m) | 4.0 (4H, m) |
| 1” | 3.71 (3H, d, JPH = 5.0) | 1.66 (4H, m) | 1.66 (4H, m) | |
| 2’ | - | 1.3 (6H, t, J = 9.3) | ||
| 3’ | - | - | 0.93 (6H, t, J = 7.5) | 1.36 (4H, m) |
| 4’ | - | - | - | 0.95 (6H, t, J = 7.5) |
13C NMR spectra data for derivatives 17–20 (127.76 MHz, CDCl3, δ, ppm) (P, J/Hz).
| C Atom | 17 | 18 | 19 | 20 |
|---|---|---|---|---|
| 1 | 2 | 3 | 4 | 5 |
| 1 | 44.2 d | 44.2 d | 44.2 d | 44.2 d |
| 2 | 32.6 t | 32.6 t | 32.6 t | 32.6 t |
| 3 | 63.0 d | 63.1 d | 63.0 d | 63.0 d |
| 4 | 65.8 s | 65.8 s | 65.8 s | 65.8 s |
| 5 | 50.3 d | 50.4 d | 50.3 d | 50.3 d |
| 6 | 80.9 d | 80.8 d | 80.8 d | 80.8 d |
| 7 | 47.7 d (d, J = 4.0) | 47.6 d (d, J = 3.7) | 47.7 d (d, J = 3.4) | 47.7 d (d, J = 4.7) |
| 8 | 30.2 t | 30.3 t | 30.4 t | 30.4 t |
| 9 | 30.5 t | 30.7 t | 30.7 t | 30.7 t |
| 10 | 146.7 s | 146.7 s | 146.7 s | 146.8 s |
| 11 | 41.8 d (d, J = 4.2) | 42.0 d (d, J = 4.3) | 42.0 d (d, J = 4.3) | 42.0 d (d, J = 4.3) |
| 12 | 176.4 s | 176.6 | 176.5 | 176.5 s |
| 13 | 24.1 t (d, J = 145.5) | 25.1 t (d, J = 145.2) | 25.0 t (d, J = 145.2) | 25.0 t (d, J = 143.6) |
| 14 | 114.2 t | 114.2 t | 114.2 t | 114.1 t |
| 15 | 18.5 q | 18.6 q | 18.6 q | 18.6 q |
| 1’ | 52.7 q (d, J = 6.7) | 62.1 t (d, J = 6.7) | 67.5 t (d, J = 6.7) | 65.8 t (d, J = 6.7) |
| 1” | 52.2 q (d, J = 6.7) | 61.7 t (d, J = 6.7) | 67.1 t (d, J = 6.7) | 65.41 t (d, = 6.7) |
| 2’ | - | 16.3 q | 23.7 t | 32.4 t |
| 2” | - | 16.2 q | 23.7 t | 32.3 t |
| 3’ | - | - | 10.0 q | 18.6 t |
| 3” | - | - | 10.0 q | 18.6 t |
| 4’ | - | - | - | 13.5 q |
| 4” | - | - | - | 13.5 q |
Figure 4Structures of amino derivatives of estafiatin 21–25.
Figure 5Structures of amino derivatives of estafiatin 26–30.
Figure 6Obtaining of cytisinylestafiatin 31.
Figure 7Obtaining of anabasinylestafiatin 32.
Figure 8Spatial structure of molecules 33 and 34 according to X-ray diffraction analysis data.
Ligand efficiency and values of the estimated binding energy of the complexes of the studied compounds with the receptors DNA topoisomerase I and DNA topoisomerase II.
| Compound | Receptor DNA Topoisomerase I | Receptor DNA Topoisomerase II | ||
|---|---|---|---|---|
| Estimated Binding Energy, | Ligand Efficiency | Estimated Binding Energy, kcal/mol | Ligand Efficiency | |
|
| −6.439 | 0.36 | −7.721 | 0.43 |
|
| −7.168 | 0.40 | −8.542 | 0.47 |
|
| −6.643 | 0.37 | −8.013 | 0.45 |
|
| −7.041 | 0.34 | −6.802 | 0.32 |
|
| −6.494 | 0.36 | −8.286 | 0.46 |
|
| −7.013 | 0.37 | −7.951 | 0.42 |
|
| −6.132 | 0.28 | −7.721 | 0.41 |
|
| −6.485 | 0.34 | −5.827 | 0.26 |
|
| −6.421 | 0.34 | −7.592 | 0.40 |
|
| −6.368 | 0.34 | −7.659 | 0.40 |
|
| −6.261 | 0.31 | −8.458 | 0.42 |
|
| −6.057 | 0.30 | −7.941 | 0.40 |
|
| −6.224 | 0.33 | −7.763 | 0.41 |
|
| −6.106 | 0.32 | −7.429 | 0.39 |
|
| −5.865 | 0.24 | −6.384 | 0.25 |
|
| −5.616 | 0.22 | −7.397 | 0.31 |
|
| −5.733 | 0.20 | −5.013 | 0.18 |
|
| −5.609 | 0.19 | −5.992 | 0.20 |
|
| −5.754 | 0.24 | −3.833 | 0.16 |
|
| −4.625 | 0.22 | −6.859 | 0.33 |
IC50 antitumor activity of estafiatin 1 and its derivatives.
| Compound | 1 | 2 | 3 | 4 | 5 | 6 | 11 | 13 | 15 |
|---|---|---|---|---|---|---|---|---|---|
| Pliss lymphosarcoma (IC50), µM | 4.62 ± 1.42 | 4.65 ± 1.01 | 2.68 ± 0.92 | 0.04 ± 0.01 | 4.34 ± 1.73 | 5.09 ± 1.70 | 4.82 ± 1.35 | 1.84 ± 0.18 | 4.19 ± 1.03 |
| Walker’s carcinosarcoma (IC50), µM | 2.13 ± 0.94 | 4.27 ± 1.58 | 5.16 ± 1.52 | 4.93 ± 0.92 | 1.34 ± 0.12 | 5.51 ± 1.47 | +infinity | 8.37 ± 1.92 | 3.00 ± 1.42 |
| Sarcoma 45 (IC50), µM | 4.37 ± 1.26 | 3.69 ± 1.05 | 3.34 ± 0.98 | 2.96 ± 0.75 | 3.86 ± 1.79 | 3.97 ± 1.04 | 4.69 ± 1.42 | 2.59 ± 0.75 | 2.00 ± 0.98 |
| PC-1 alveolar liver cancer (IC50), µM | 3.05 ± 1.67 | 5.09 ± 1.75 | 3.05 ± 0.86 | 4.69 ± 1.01 | 3.05 ± 0.90 | 3.61 ± 1.75 | 2.96 ± 0.51 | 2.80 ± 0.38 | 3.17 ± 1.04 |
| Sarcoma 37 (IC50), µM | 3.86 ± 0.97 | 2.20 ± 0.09 | 4.34 ± 1.45 | 3.05 ± 1.08 | 2.96 ± 0.07 | 3.05 ± 1.05 | 0.03 ± 0.01 | 3.17 ± 1.22 | 2.96 ± 1.15 |
| Sarcoma 180 (IC50), µM | 3.05 ± 1.10 | 4.52 ± 1.42 | 2.96 ± 1.01 | 2.96 ± 1.07 | 0.04 ± 0.01 | 2.96 ± 0.87 | 2.55 ± 0.90 | 4.52 ± 1.68 | 3.61 ± 1.47 |
| Leukemia P-388 (IC50), µM | 3.62 ± 1.21 | 2.92 ± 1.09 | 2.96 ± 0.95 | 17.94 ± 2.57 | - | - | - | 1.69 ± 0.15 | 4.52 ± 1.25 |
| Leukemia L-1210 (IC50), µM | 2.92 ± 1.22 | - | 2.42 ± 0.91 | 1.98 ± 0.06 | - | - | - | 4.52 ± 1.59 | 2.79 ± 0.69 |
| Sarcoma 45 to 5-fluoro-uracil (IC50), µM | 3.05 ± 1.47 | - | 2.29 ± 0.72 | 5.09 ± 2.03 | - | - | - | 1.30 ± 0.11 | 1.30 ± 0.08 |
- reliability of differences p < 0.05 compared with the comparison group.
Antitumor activity on transplanted tumor strains of estafiatin 1 and its derivatives.
| Compound | Dose | Pliss Lymphosarcoma | Walker’s Carcinosarcoma | Sarcoma 45 | PC-1 Alveolar Liver Cancer | Sarcoma 37 | Sarcoma 180 | Leukemia P-388 | Leukemia L-1210 | Sarcoma 45 to 5-Fluoro- |
|---|---|---|---|---|---|---|---|---|---|---|
|
| 20 | 23.3 ± 1.45 | 59.9 ± 1.04 | 31.2 ± 0.32 | 55.0 ± 1.77 | 15.1 ± 0.14 | 26.4 ± 0.17 | 16.1 ± 0.02 | 12.4 ± 1.12 | 21.3 ± 0.19 |
|
| 20 | 80.0 ± 1.04 | 55.9 ± 1.40 | 51.2 ± 1.21 | 63.0 ± 1.60 | 25.3 ± 1.72 | 41.3 ± 1.41 | 96.0 ± 2.75 | - | - |
|
| 20 | 68. 7 ± 0.94 | 69.1 ± 1.26 | 68.9 ± 1.10 | 68.2 ± 1.33 | 29.6 ± 1.50 | 81.5 ± 1.72 | 81.5 ± 2.07 | 45.0 ± 1.06 | 88.9 ± 1.64 |
|
| 30 | 73.1 ± 1.83 | 64.0 ± 1.42 | 52.0 ± 1.92 | 70.4 ± 0.15 | 84.0 ± 2.43 | 55.5 ± 2.01 | 79.4 ± 1.92 | 23.1 ± 0.05 | 76.2 ± 2.77 |
|
| 25 | 71.1 ± 1.93 | 59.0 ± 1.61 | 48.1 ± 0.47 | 79.0 ± 0.09 | 36.0 ± 1.05 | 74.1 ± 2.32 | - | - | - |
|
| 25 | 81.4 ± 1.45 | 67.9 ± 0.75 | 50.1 ± 1.67 | 56.8 ± 2.45 | 32.0 ± 1.97 | 50.0 ± 0.99 | - | - | - |
|
| 30 | 41.1 ± 0.83 | 51.3 ± 1.32 | 21.4 ± 0.05 | 70.0 ± 1.90 | 42.1 ± 2.00 | 61.0 ± 1.67 | - | - | - |
|
| 25 | 68.9 ± 0.71 | 83.0 ± 1.53 | 90.9 ± 1.01 | 43.6 ± 2.01 | 49.4 ± 1.47 | 72.1 ± 2.04 | 104.0 ± 2.90 | 62.0 ± 1.70 | 75.7 ± 2.70 |
|
| 25 | 80.0 ± 1.05 | 80.3 ± 1.50 | 47.0 ± 1.00 | 24.1 ± 1.04 | 36.0 ± 0.58 | 72.7 ± 1.92 | 81.0 ± 1.55 | 50.0 ± 1.82 | 75.7 ± 1.90 |
|
| 2 | 54.4 ± 1.24 | 30.1 ± 1.47 | 20.4 ± 0.12 | 26.5 ± 1.52 | 36.7 ± 0.06 | 14.4 ± 0.18 |
Note: (–)-no activity was detected, -reliability of differences p < 0.05 compared with the comparison group.